

Printed as of 5/9/2025

Harvard Medical School

Disclosures

Personal Commercial (18)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------------|--|
| Self | | | |
| Abbott Laboratories | Research/Research Grants ‡ Pilot Study | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Abbott Laboratories | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| AbbVie, Inc. | Data Safety Monitoring Board | Significant (>= \$5,000) | General Cardiology |
| Abiomed | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Bayer Healthcare Pharmaceuticals | Data Safety Monitoring Board | Modest (< \$5,000) | General Cardiology |
| CVRx | Data Safety Monitoring Board | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Eli Lilly and Company | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Imbria | Officer, Director, Trustee, or other Fiduciary Role | Significant (>= \$5,000) | Stable Ischemic Heart Disease |
| Jana Care | Officer, Director, Trustee, or other Fiduciary Role | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Janssen Pharmaceuticals, Inc | Research/Research Grants | Significant (>= \$5,000) | Prevention |
| Medtronic | Research/Research Grants | Modest (< \$5,000) | Valvular Heart Disease |
| Novartis | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Novo Nordisk Inc. | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Prevencio | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Roche Diagnostics | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies General Cardiology |
| Siemens | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Takeda Pharmaceuticals North America, Inc | Data Safety Monitoring Board | Significant (>= \$5,000) | General Cardiology |
| | | | |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/26/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/26/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 8/26/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.